Compare CYRX & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | ANGO |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.7M | 400.8M |
| IPO Year | N/A | 2004 |
| Metric | CYRX | ANGO |
|---|---|---|
| Price | $9.40 | $13.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $12.83 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 590.7K | 465.8K |
| Earning Date | 11-04-2025 | 01-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | $243,795,000.00 | ★ $300,718,000.00 |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | $9.26 | $5.15 |
| P/E Ratio | $7.44 | ★ N/A |
| Revenue Growth | ★ 41.27 | 2.73 |
| 52 Week Low | $4.58 | $8.27 |
| 52 Week High | $11.44 | $13.99 |
| Indicator | CYRX | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 58.82 |
| Support Level | $9.08 | $13.12 |
| Resistance Level | $10.30 | $13.53 |
| Average True Range (ATR) | 0.46 | 0.43 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 42.94 | 61.80 |
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.